Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (March 2014)
22 slides from Impedimed's investor presentation, Mar 19, 2014
Slide 1: Investor Presentation
For personal use only Investor Presentation ASX:IPD March 2014
Slide 2: Disclaimer
Disclaimer This presentation has been produced by ImpediMed Limited (“ImpediMed”) only and may contain forward-looking statements that are based on For personal use only management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual res
Slide 3: Investment Summary
Investment Summary • ImpediMed’s bioimpedance spectroscopy (BIS) system accurately and simply measures tissue composition (muscle, fluid, fat) For personal use only • Numerous medical and non-medical uses • Current methods of measuring tissue composition are rudimentary/unreliable or expensive/ comp
Slide 4: Corporate Snapshot
Corporate Snapshot • ASX listed (Since October 2007) Share Price Performance – LTM $/Sh Volume (000's) For personal use only • Operations in US (San Diego) and Aus (Brisbane) • Transformed Board & Management in 2013 • 25 FTE staff • Market capitalisation ~$40m (181m shares on Issue) • Cash on hand $
Slide 5: BIS Measures Tissue Composition
BIS Measures Tissue Composition • Measurements using For personal use only bioimpedance at a single frequency is used to estimate body composition (limited capabilities) • However, multiple frequencies are required to obtain complete information of tissue composition Low Frequency High Frequency • I
Slide 6: Current Approaches Have Major Limitations
Current Approaches Have Major Limitations • High Tech: - e.g. X-Ray absorptiometry; For personal use only CT scan; MRI scan; isotope dilution (lymphoscintigraphy); perometry* • Effective and accurate Lymphoscintigraphy • Expensive • Time consuming Perometry • Radiation exposure / toxic chemicals • C
Slide 7: Advantages of BIS are Compelling
Advantages of BIS are Compelling • Informative – 256 frequency spectra provides For personal use only detailed measurements of muscle, fluid, and fat • Simple to Use – easy placement of electrodes • Fast – 5-10 mins to measure • Non-invasive – no dyes or radiation • Safe – no safety concerns reporte
Slide 8: First Commercial Product: L-Dex for Lymphoedema
First Commercial Product: L-Dex for Lymphoedema • Lymphoedema is a progressive swelling that can occur following For personal use only cancer treatment due to lymph nodes being removed, damaged or irradiated • Lymphoedema can become a chronic, debilitating, life-long condition • Lymphoedema affects
Slide 9: L-Dex Allows Early Detection of Lymphoedema
L-Dex Allows Early Detection of Lymphoedema • Current techniques used to assess lymphoedema measure only total For personal use only limb volume • Don't distinguish between muscle, fluid and fat • Cannot detect lymphoedema before it is visibly apparent (sub-clinical lymphoedema) • L-Dex directly mea
Slide 10: L-Dex Provides Significant Advantages
L-Dex Provides Significant Advantages For personal use only Direct Volume Ease for Detects Standardised Measure of Change Easily Regulatory Patients, Standard of Method Sub-Clinical Detection Portable Extracellular Required for Reproducible Clearance Non- Care (Stage 0) Criteria Fluid Detection inva
Slide 11: The Importance of Early Detection
The Importance of Early Detection “BIS is a significant leap in technology. It is able to detect lymphoedema at the earliest For personal use only possible stage of development (stage 0) where treatment is the most effective, and can potentially stabilise or even reverse the early stage lymphoedema.
Slide 12: Third Party Trials Generating L-Dex Data
Third Party Trials Generating L-Dex Data United States For personal use only • 2 randomised controlled trials (n ~100 each site) being conducted at large teaching hospitals • Both investigating whether early intervention, identified with BIS, halts the progression of lymphoedema • Comparison between
Slide 13: ImpediMed's Post Market Approval Trial
ImpediMed’s Post Market Approval Trial • To help drive adoption ImpediMed is also sponsoring an For personal use only international trial • Large (n=1,000), multi-centre randomised controlled trial to prove that use of BIS to enable early treatment reduces progression of lymphoedema • Straightforwar
Slide 14: Cancer Related Lymphoedema Market
Cancer Related Lymphoedema Market For personal use only Annual Cancer Incidences1 United States Breast Cancer (women) 232,000 Upper Limbs Pelvic Cancers2 630,000 Lower Limbs Melanoma (women & men) 77,000 Upper and Lower Limbs Total 939,000 Rest of World Market3 is more than 5 times the US Market 1.
Slide 15: L-Dex's Growing Acceptance
L-Dex’s Growing Acceptance Key position statements on early detection of For personal use only lymphoedema - recommendations for BIS • Australasian Lymphology Association (ALA), Aus • National Lymphedema Network (NLN), US • National Accreditation Program for Breast Centers (NAPBC), US Formally publi
Slide 16: Recent Game Changing US Milestones
Recent Game Changing US Milestones For personal use only Unencumbered FDA clearance June 2013 • Removed The device is not intended to diagnose or predict lymphoedema of the extremity American Medical Association October 2013 CPT Editorial Panel Meeting • Accepted addition of Category I code • CPT Ca
Slide 17: Commercialisation of L-Dex
Commercialisation of L-Dex • United States For personal use only • Direct sales force • Establish synergistic distribution and product alliances • Initial focus on breast cancer market (2,700 - American Society of Breast Surgeons) • Expansion into lower limb lymphoedema (10,500 oncologists) • CPT Ca
Slide 18: Global Opportunities for BIS
Global Opportunities for BIS Current Opportunities Future Opportunities For personal use only • Lymphoedema • Dialysis • Fluid status detection and monitoring • Accurate fluid volume and management of patient nutrition • Nutrition • Fat versus lean body mass and fluid • Venous Insufficiency balance
Slide 19: Financials
Financials H1 FY2014 H1 FY2013 % Change $000 $000 For personal use only Lymphoedema Revenue 756 549 38% Body Composition Revenue 307 322 5% Test & Measurement Revenue 548 392 40% Total Group Revenue 1,611 1,263 28% Operating Expenses 4,505 5,709 21% Operating Loss 3,586 5,165 31% Lymphoedema Revenue
Slide 20: Management
Management Rick Carreon • Joined July 2012 President and Chief Executive • 30+ years experience For personal use only Officer • Extensive experience in the medical device field and growth companies • Previously Vice President at Medtronic (10 years) Morten Vigeland • Joined April 2011 Chief Financia
Slide 21: Board of Directors
Board of Directors Cherrell Hirst AO • On Board since 2005 FTSE, MBBS, BEdSt, D.Univ • Appointed Non-Executive Chairman in Nov 2011 For personal use only (Hon), FAICD • Leading medical practitioner in breast cancer screening/diagnosis Non-Executive Chairman • Currently a Director of Tissue Therapies
Slide 22: 2014 and 2015 Key Drivers
2014 and 2015 Key Drivers For personal use only • Accelerating revenue in the US on the back of the CPT I code • Medicare reimbursement expected January 2015 • Building private payor adoption • Increasing profile in cancer survivorship guidelines • Results of third party trials published • Post appr